226 related articles for article (PubMed ID: 25817923)
1. Review of STAT3 (Signal Transducers and Activators of Transcription) in head and neck cancer.
Mali SB
Oral Oncol; 2015 Jun; 51(6):565-9. PubMed ID: 25817923
[TBL] [Abstract][Full Text] [Related]
2. Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies: implications for future therapeutic approaches.
Lai SY; Johnson FM
Drug Resist Updat; 2010 Jun; 13(3):67-78. PubMed ID: 20471303
[TBL] [Abstract][Full Text] [Related]
3. Targeting constitutive and interleukin-6-inducible signal transducers and activators of transcription 3 pathway in head and neck squamous cell carcinoma cells by curcumin (diferuloylmethane).
Chakravarti N; Myers JN; Aggarwal BB
Int J Cancer; 2006 Sep; 119(6):1268-75. PubMed ID: 16642480
[TBL] [Abstract][Full Text] [Related]
4. STAT3 activation abrogates growth factor dependence and contributes to head and neck squamous cell carcinoma tumor growth in vivo.
Kijima T; Niwa H; Steinman RA; Drenning SD; Gooding WE; Wentzel AL; Xi S; Grandis JR
Cell Growth Differ; 2002 Aug; 13(8):355-62. PubMed ID: 12193474
[TBL] [Abstract][Full Text] [Related]
5. Complex regulation of signal transducers and activators of transcription 3 activation in normal and malignant keratinocytes.
Quadros MR; Peruzzi F; Kari C; Rodeck U
Cancer Res; 2004 Jun; 64(11):3934-9. PubMed ID: 15173005
[TBL] [Abstract][Full Text] [Related]
6. The STAT3 pathway as a therapeutic target in head and neck cancer: Barriers and innovations.
Geiger JL; Grandis JR; Bauman JE
Oral Oncol; 2016 May; 56():84-92. PubMed ID: 26733183
[TBL] [Abstract][Full Text] [Related]
7. STAT signaling in head and neck cancer.
Song JI; Grandis JR
Oncogene; 2000 May; 19(21):2489-95. PubMed ID: 10851047
[TBL] [Abstract][Full Text] [Related]
8. Phosphorylation of STAT3 in head and neck cancer requires p38 MAPKinase, whereas phosphorylation of STAT1 occurs via a different signaling pathway.
Riebe C; Pries R; Schroeder KN; Wollenberg B
Anticancer Res; 2011 Nov; 31(11):3819-25. PubMed ID: 22110204
[TBL] [Abstract][Full Text] [Related]
9. Molecular cross-talk between the NFkappaB and STAT3 signaling pathways in head and neck squamous cell carcinoma.
Squarize CH; Castilho RM; Sriuranpong V; Pinto DS; Gutkind JS
Neoplasia; 2006 Sep; 8(9):733-46. PubMed ID: 16984731
[TBL] [Abstract][Full Text] [Related]
10. Signal transducers and activators of transcription 3 up-regulates vascular endothelial growth factor production and tumor angiogenesis in head and neck squamous cell carcinoma.
Masuda M; Ruan HY; Ito A; Nakashima T; Toh S; Wakasaki T; Yasumatsu R; Kutratomi Y; Komune S; Weinstein IB
Oral Oncol; 2007 Sep; 43(8):785-90. PubMed ID: 17169602
[TBL] [Abstract][Full Text] [Related]
11. STAT 3 activation in head and neck squamous cell carcinomas is controlled by the EGFR.
Hambek M; Baghi M; Strebhardt K; May A; Adunka O; Gstöttner W; Knecht R
Anticancer Res; 2004; 24(6):3881-6. PubMed ID: 15736426
[TBL] [Abstract][Full Text] [Related]
12. Iressa (ZD 1839) inhibits phosphorylation of three different downstream signal transducers in head and neck cancer (SCCHN).
Hambek M; Baghi M; Baumaun H; Strebhardt K; Adunka O; Gstöttner W; Knecht R
Anticancer Res; 2005; 25(3B):1871-5. PubMed ID: 16158919
[TBL] [Abstract][Full Text] [Related]
13. Guggulsterone (GS) inhibits smokeless tobacco and nicotine-induced NF-κB and STAT3 pathways in head and neck cancer cells.
Macha MA; Matta A; Chauhan SS; Siu KW; Ralhan R
Carcinogenesis; 2011 Mar; 32(3):368-80. PubMed ID: 21177768
[TBL] [Abstract][Full Text] [Related]
14. Constitutive activation of signal transducers and activators of transcription 3 correlates with cyclin D1 overexpression and may provide a novel prognostic marker in head and neck squamous cell carcinoma.
Masuda M; Suzui M; Yasumatu R; Nakashima T; Kuratomi Y; Azuma K; Tomita K; Komiyama S; Weinstein IB
Cancer Res; 2002 Jun; 62(12):3351-5. PubMed ID: 12067972
[TBL] [Abstract][Full Text] [Related]
15. Erythropoietin-mediated activation of JAK-STAT signaling contributes to cellular invasion in head and neck squamous cell carcinoma.
Lai SY; Childs EE; Xi S; Coppelli FM; Gooding WE; Wells A; Ferris RL; Grandis JR
Oncogene; 2005 Jun; 24(27):4442-9. PubMed ID: 15856028
[TBL] [Abstract][Full Text] [Related]
16. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention.
Buettner R; Mora LB; Jove R
Clin Cancer Res; 2002 Apr; 8(4):945-54. PubMed ID: 11948098
[TBL] [Abstract][Full Text] [Related]
17. In vivo antitumor efficacy of STAT3 blockade using a transcription factor decoy approach: implications for cancer therapy.
Xi S; Gooding WE; Grandis JR
Oncogene; 2005 Feb; 24(6):970-9. PubMed ID: 15592503
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of STAT-3 results in greater cetuximab sensitivity in head and neck squamous cell carcinoma.
Bonner JA; Yang ES; Trummell HQ; Nowsheen S; Willey CD; Raisch KP
Radiother Oncol; 2011 Jun; 99(3):339-43. PubMed ID: 21704410
[TBL] [Abstract][Full Text] [Related]
19. Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer.
Haura EB; Zheng Z; Song L; Cantor A; Bepler G
Clin Cancer Res; 2005 Dec; 11(23):8288-94. PubMed ID: 16322287
[TBL] [Abstract][Full Text] [Related]
20. Constitutive activation of Stat3 in fibroblasts transformed by diverse oncoproteins and in breast carcinoma cells.
Garcia R; Yu CL; Hudnall A; Catlett R; Nelson KL; Smithgall T; Fujita DJ; Ethier SP; Jove R
Cell Growth Differ; 1997 Dec; 8(12):1267-76. PubMed ID: 9419415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
